Scroll down to see more

About Laekna

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company.

Laekna has two Core Products and 13 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The other Core Product LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2(CYP11B2) for the treatment of prostate cancer.

Laekna has initiated one registrational clinical trial and another five clinical trials for our Core Products LAE002 and LAE001. Among these six clinical trials, three are multi-regional clinical trials (MRCTs) designed to address medical needs in the standard of care (SOC)-resistant cancers.

As of the Latest Practicable Date, Laekna owned 163 patents and patent applications (including in-licensed patents and patent applications with global rights).

Laekna’s internal drug discovery primarily focuses on identifying innovative immunology therapies for cancer and liver fibrosis.

Our Vision
Our Vision

We are committed to becoming
an innovative 
biopharmaceutical company
that can bring novel therapies
to cancer and liver fibrosis 
patients worldwide.

Core Management Team

Glossary & abbreviations

MCRPC: metastatic castration-resistant prostate cancer IND: investigational new drug MRCT: multi-regional clinical trial PROC: platinum-resistant ovarian cancer TNBC: triple negative breast cancer ActRIIA: activin receptor type IIA HR+/HER2- breast cancer: the most common type of breast cancer with overexpression of HR and without overexpression of HER2
Scientific Advisory Board
Peter ten Dijke
  • Last :Peter ten Dijke
  • Next :Jeff Porter
Honors & Awards
  • 2022

    2022 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    2022 Pioneers: The Scientists

    KPMG China Future 50 - Biotech

  • 2021

    2021 China Corporate Social Responsibility Virtual Summit - CSR Good Practice

    2021 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises

    Pioneers to the Star 2021 Biomedicine Pioneer-10

    Frost & Sullivan 2021 Top 100 Technology Leaders - Top 50 Innovative Technology Leaders

  • 2020

    Top 20 Disruptive Technologies in Cancer

  • 2019

    China Healthcare Industry Investment and Financing Honor List: Top 20 Emerging Healthcare Companies

  • 2018

    2018 Insights Zhangjiang Top 100

  • 图片1
  • 图片2
  • 图片3
  • 图片4
  • 图片6
  • 图片7
  • 图片8
  • 图片9
  • Last:Peter ten Dijke
  • Next:Jeff Porter
  • Last:Peter ten Dijke
  • Next:Jeff Porter
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin